KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Bionano Genomics (BNGO) Accumulated Depreciation & Amortization (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Accumulated Depreciation & Amortization for 9 consecutive years, with $28.2 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 101.11% to $28.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.2 million through Dec 2025, up 101.11% year-over-year, with the annual reading at $28.2 million for FY2025, 101.11% up from the prior year.
  • Accumulated Depreciation & Amortization hit $28.2 million in Q4 2025 for Bionano Genomics, up from $14.0 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $28.2 million in Q4 2025 to a low of -$17.4 million in Q3 2024.
  • Historically, Accumulated Depreciation & Amortization has averaged $8.6 million across 5 years, with a median of $11.7 million in 2022.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 187.11% in 2022 and later rose 2.29% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $3.4 million in 2021, then soared by 187.11% to $9.6 million in 2022, then skyrocketed by 42.48% to $13.7 million in 2023, then rose by 2.29% to $14.0 million in 2024, then skyrocketed by 101.11% to $28.2 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for BNGO at $28.2 million in Q4 2025, $14.0 million in Q4 2024, and -$17.4 million in Q3 2024.